Solid Biosciences SLDB
NASDAQ SLDB
$7.23 +0.07 (+0.98%)
At close: Sep 30, 2026 · 4:00 PM EDT

Solid Biosciences (SLDB) Revenue (2022)

Updated

Solid Biosciences' Revenue was $8.09 million in FY2022, down 40.6% from $13.62 million in FY2021.

Analysis

Solid Biosciences (SLDB) Revenue (2022) Analysis & Trends

  • Per Business Quant data, Revenue in earlier years was $13.62 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 25.31 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 16.99 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 16.61 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 14.41 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 15.38 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 10.05 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 7.80 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 15.03 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 3.33 Bn
10 Solid Biosciences 1.03 Bn 1.03 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 6.17 Mn
API Access

Solid Biosciences Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=SLDB&period=max&api_key=YOUR_API_KEY